Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of AL101 in Healthy Volunteers
NCT04111666Phase 1Completed
- Sponsor
- Alector
- Start
- Dec 2019
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of nivisnebart in Alzheimer's disease (AD), Parkinson's disease (PD) and frontotemporal dementia (FTD) (4 arms), sponsored by Alector. Primary endpoint: Evaluation of safety and tolerability of AL101 at 141 days. Started Dec 2019; status: completed.
02
Drugs
nivisnebart
03
Conditions
Alzheimer's disease (AD)Parkinson's disease (PD)frontotemporal dementia (FTD)
Beyond the preview
Go deeper on NCT04111666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04111666.